Клинические и фармакоэкономические аспекты терапии сердечной недостаточности селективным антагонистом альдостерона эплереноном

1. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Современный образ пациента с ХСН в Европейской части Российской Федерации (госпитальный этап). Сердечная недостаточность. 2011; 5.
2. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report fr om the American Heart Association. Circulation 2010; 121: e46–215.
3. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: wh ere are the theories and trials leading us? Heart 2000; 83: 76–80.
4. Bolognese L, Neskovic A, Parodi G et al. Left Ventricular Remodeling After Primary Coronary Angioplasty Patterns of Left Ventricular Dilation and Long-Term Prognostic Implications. Circulation 2002; 106: 2351–7.
5. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 
100 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202–12.
6. Latini R, Tognoni G, Maggioni AP et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96 712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35 (7): 1801–7.
7. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115 (6): 473–9.
8. Exner DV, Dries DL, Waclawiw MA et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 1999; 33 (4): 916–23.
9. Vantrimpont P, Rouleau JL, Wun CC et al. SAVE Investigators Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997; 29 (2): 229–36.
10. Baker WL, Coleman CI, Kluger J et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009. Published online ahead of print.
11. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64.
12. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101: 378–84.
13. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity andmortality in patients with severe heart failure. New Engl
J Med 1999; 341 (10): 709–17.
14. Juurlink DN, Mamdani MM, Lee DS et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–51.
15. Pitt B, White Н, Nicolau J et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol 2005; 46: 425–31.
16. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
17. Рудакова А.В., Моисеева О.М. Эффективность затрат при терапии селективным антагонистом альдостерона эплереноном больных с сердечной недостаточностью. Артериальная гипертензия. 2012; 18 (2): 108–17.
18. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization 2001.
19. McKenna C, Burch J, Suekarran S et al. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. Health Technol Assess 2010; 14 (24).
20. De Pouvourville G, Solesseb A, Beillat M. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study. Arch Cardiovasc Dis 2008; 101: 515–21.
21. Weintraub W, Zhang Z, Mahoney E et al. Cost-Effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005; 111: 1106–13.
22. Croom K, Plosker G. Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. Pharmacoeconomics 2005; 23 (10): 1057–72.
23. Szucs T, Holm M, Schwenkglenks M et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction – an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006; 20 (3): 193–204.
24. Pitt B, Gheorghiade M, Zannad F et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Failure 2006; 8: 295–301.
25. Zannad F, McMurray JJV, Krum H et al. EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. 
N Engl J Med 2011; 364: 11–21.
26. Krum H, Shi H, Pitt B et al. Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study. Circ Heart Fail 2013; 6: 711–8.
27. Collier T, Pocock S, McMurray J et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013; 34: 2823–9.
28. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
29. Girerd N, Collier T, Pocock S et al. Clinical benefits of Eplerenone in patients with systolic NYHA II heart failure when initiated shortly after hospital discharge. Eur Heart J 2013; 34: P3304.
30. Pitt B, Zannad F. Eplerenone: is it time to add this drug to current heart failure therapy? Ther Adv Chron Disease 2012; 3: 5.
31. Gheorghiade M, Khan S, Blair J et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J 2009; 158: 437–43.

А.В.Рудакова1, О.М.Моисеева2

1. ГБОУ ВПО Санкт-Петербургская государственная химико-фармацевтическая академия Минздрава России;
2. ФГБУ Федеральный медицинский исследовательский центр им. В.А.Алмазова, Санкт-Петербург